{"name":"Betta Pharmaceuticals","slug":"betta-pharma","ticker":"300558.SZ","exchange":"SZSE","domain":"bettapharma.com","description":"Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of NSCLC; and Bevacizumab, an antibody drug against human vascular endothelial growth factor that is used to treat NSCLC, colorectal cancer, and other solid tumor indications. It also develops BPI-D0316, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeting T790M mutation; EYP-1901, an investigational long-acting treatment for wet AMD, non-proliferative diabetic retinopathy, diabetic macular edema, and pmCNV; and MCLA-129, a bispecific antibody targeting both EGFR and c-Met. In addition, the company develops BPI-371153 for the tre","hq":"Hangzhou, Zhejiang, China","founded":2015,"employees":"1785","ceo":"Lu Xian","sector":"Oncology / Specialty Pharma","stockPrice":50.1,"stockChange":-1.13,"stockChangePercent":-2.21,"marketCap":"$3.1B","metrics":{"revenue":549972661.5268506,"revenueGrowth":13.3,"grossMargin":79,"rdSpend":0,"netIncome":65018474.74775264,"cash":75198984.87875615,"dividendYield":0.39,"peRatio":47.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Betta-1 patent cliff ($1.2B at risk)","drug":"Betta-1","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Betta-2 patent cliff ($800M at risk)","drug":"Betta-2","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Icotinib plus WBRT","genericName":"Icotinib plus WBRT","slug":"icotinib-plus-wbrt","indication":"Non-small cell lung cancer with EGFR mutations and brain metastases (in combination with whole-brain radiotherapy)","status":"marketed"},{"name":"Maintenance icotinib","genericName":"Maintenance icotinib","slug":"maintenance-icotinib","indication":"Maintenance therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations","status":"marketed"},{"name":"Sequential Icotinib Plus Chemotherapy","genericName":"Sequential Icotinib Plus Chemotherapy","slug":"sequential-icotinib-plus-chemotherapy","indication":"Non-small cell lung cancer with EGFR mutations","status":"marketed"},{"name":"BPI-16350","genericName":"BPI-16350","slug":"bpi-16350","indication":"Cholangiocarcinoma with FGFR2 fusion or rearrangement","status":"phase_3"},{"name":"Icotinib Hydrochloride Tablets","genericName":"Icotinib Hydrochloride Tablets","slug":"icotinib-hydrochloride-tablets","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Icotinib with concurrent radiotherapy","genericName":"Icotinib with concurrent radiotherapy","slug":"icotinib-with-concurrent-radiotherapy","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Sequential and maintenance icotinib","genericName":"Sequential and maintenance icotinib","slug":"sequential-and-maintenance-icotinib","indication":"Non-small cell lung cancer (NSCLC) with EGFR mutations","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"1.0% Icotinib hydrochloride cream","genericName":"1.0% Icotinib hydrochloride cream","slug":"1-0-icotinib-hydrochloride-cream","indication":"Other","status":"phase_1"},{"name":"2-year treatment with icotinib","genericName":"2-year treatment with icotinib","slug":"2-year-treatment-with-icotinib","indication":"Other","status":"phase_2"},{"name":"Chemoradiotherapy","genericName":"Chemoradiotherapy","slug":"chemoradiotherapy","indication":"Other","status":"phase_2"},{"name":"D-0316 Capsule","genericName":"D-0316 Capsule","slug":"d-0316-capsule","indication":"Phase 2 clinical trial for treatment of unspecified condition","status":"phase_2"}]}],"pipeline":[{"name":"Icotinib plus WBRT","genericName":"Icotinib plus WBRT","slug":"icotinib-plus-wbrt","phase":"marketed","mechanism":"Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling in cancer cells, combined with whole-brain radiotherapy (WBRT) to treat brain metastases.","indications":["Non-small cell lung cancer with EGFR mutations and brain metastases (in combination with whole-brain radiotherapy)"],"catalyst":""},{"name":"Maintenance icotinib","genericName":"Maintenance icotinib","slug":"maintenance-icotinib","phase":"marketed","mechanism":"Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation.","indications":["Maintenance therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations"],"catalyst":""},{"name":"Sequential Icotinib Plus Chemotherapy","genericName":"Sequential Icotinib Plus Chemotherapy","slug":"sequential-icotinib-plus-chemotherapy","phase":"marketed","mechanism":"Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling, used sequentially with chemotherapy to treat EGFR-mutant lung cancer.","indications":["Non-small cell lung cancer with EGFR mutations"],"catalyst":""},{"name":"1.0% Icotinib hydrochloride cream","genericName":"1.0% Icotinib hydrochloride cream","slug":"1-0-icotinib-hydrochloride-cream","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"2-year treatment with icotinib","genericName":"2-year treatment with icotinib","slug":"2-year-treatment-with-icotinib","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BPI-16350","genericName":"BPI-16350","slug":"bpi-16350","phase":"phase_3","mechanism":"BPI-16350 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["Cholangiocarcinoma with FGFR2 fusion or rearrangement","Other FGFR-altered solid tumors"],"catalyst":""},{"name":"Chemoradiotherapy","genericName":"Chemoradiotherapy","slug":"chemoradiotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"D-0316 Capsule","genericName":"D-0316 Capsule","slug":"d-0316-capsule","phase":"phase_2","mechanism":"D-0316 Capsule is a small molecule that targets the molecular target.","indications":["Phase 2 clinical trial for treatment of unspecified condition"],"catalyst":""},{"name":"Icotinib Hydrochloride Tablets","genericName":"Icotinib Hydrochloride Tablets","slug":"icotinib-hydrochloride-tablets","phase":"phase_2","mechanism":"Tyrosine kinase inhibitor","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"Icotinib with concurrent radiotherapy","genericName":"Icotinib with concurrent radiotherapy","slug":"icotinib-with-concurrent-radiotherapy","phase":"phase_2","mechanism":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"Sequential and maintenance icotinib","genericName":"Sequential and maintenance icotinib","slug":"sequential-and-maintenance-icotinib","phase":"marketed","mechanism":"Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation.","indications":["Non-small cell lung cancer (NSCLC) with EGFR mutations"],"catalyst":""}],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"Betta Pharmaceuticals Receives FDA Approval for Betta-1 in the US","summary":"Betta Pharmaceuticals announced that the US FDA has approved Betta-1 for the treatment of non-small cell lung cancer.","drugName":"Betta-1","sentiment":"positive"},{"date":"2023-11-10","type":"earnings","headline":"Betta Pharmaceuticals Reports Strong Q3 2023 Earnings","summary":"Betta Pharmaceuticals reported a 25% increase in revenue for the third quarter of 2023, driven by strong sales of its oncology products.","drugName":"","sentiment":"positive"},{"date":"2023-08-25","type":"deal","headline":"Betta Pharmaceuticals Partners with Leading CRO to Expand Clinical Trials","summary":"Betta Pharmaceuticals announced a partnership with a leading contract research organization (CRO) to expand its clinical trials capabilities and accelerate the development of its pipeline products.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQRkptTlFVOWNRYmE1U1huU0JmRk5QUVdUUVF0ZVZvN1VaM2VsRjRodzFkOXdjVXJSakQ3YW96TXQ3UTN5Xzl2RkxFSGN2VHQwcFY2ZUlSSFd1bVUxbjRfSDlLY0ZWNFYwS1cxZ3NMZzE3S0FfbUFqSFNxeC1ycVktZ1o0V01TWWExdGMtZw?oc=5","date":"2025-10-02","type":"pipeline","source":"Yahoo Finance","summary":"Chinese healthcare, biotech firms flock to Hong Kong for IPOs - Yahoo Finance","headline":"Chinese healthcare, biotech firms flock to Hong Kong for IPOs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPdkVkRlRrcW1zSXRubjQxOFQwY0k0R0hQSl9fMWpwdG1SWUlzR0NNQjhJelYzMHhKWS1mSVFEamktdVFEMGJDRk5tRTdYVTB5Y1RlbFFxV3pSVTNmMWtxYlhJMlYzdHNsRlN6UUlhZmdCdWZzcnYwdGlNWlc2SEV1VGlkRllCdmtlVlRxX1dlRnVoY3Z2WFB6TzVlSXNVSi1wT212QjVSMlRJMHlFMXgwdHJHWQ?oc=5","date":"2025-09-29","type":"pipeline","source":"Moomoo","summary":"IPO News | Betta Pharmaceuticals (300558.SZ) Submits Listing Application to HKEX, Successfully Transformed into a 'Platform-Based Pharmaceutical Enterprise' - Moomoo","headline":"IPO News | Betta Pharmaceuticals (300558.SZ) Submits Listing Application to HKEX, Successfully Transformed into a 'Platf","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9GYTUwNG0xNUdNeG43UlkzVXA5WmR6THVtY1YzZVRIeGJwSGFpanVEeEJ4b08zM0d1ZXUzRWNqTURGVTFPcHpYTWFYY1U1clVrVGgyU0RLamZTZ0d3aXY1REs5QjVQdU93MWFtUk5ZMnpUOWs?oc=5","date":"2024-12-19","type":"regulatory","source":"The Pharma Letter","summary":"Xcovery’s Ensacove approved by FDA - The Pharma Letter","headline":"Xcovery’s Ensacove approved by FDA","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNcDB4ZFl0OElQSjNHd0x4NTRqSXdVMlZfVkxLRlZnYk4wZzZnSl81YVlaWDEySXh6OGxIdzRrNUNXVDhXM2lFdnlRdlRkQTdGTFVvcmlXNDQ1dllZSGt0N21HUWdfZDdCSnRfMUI0Z1ZkdWVocWlLZGdteGo0bTFaV001TGdVbDNsVGpERHZDc2Z0OHc1UzlYam9TOXJIV29TWWc5UjRWUXQ?oc=5","date":"2024-11-04","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Roche, Novartis lead 2024’s top 50 pharma in oncology (YTD) - drugdiscoverytrends.com","headline":"Roche, Novartis lead 2024’s top 50 pharma in oncology (YTD)","sentiment":"neutral"}],"patents":[{"drugName":"Betta-1","drugSlug":"generic-name-not-available","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Betta-2","drugSlug":"generic-name-not-available","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"China","annualRevenue":800000000}],"drugCount":11,"phaseCounts":{"marketed":4,"phase_1":1,"phase_2":5,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BeiGene","Innovent Biologics","Hengrui Pharmaceuticals"],"therapeuticFocus":["Oncology","Specialty Pharma"],"financials":{"source":"yahoo_finance","revenue":531950707.9412195,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":531950707.9412195},{"period":"2024-12-31","value":426220726.2626797},{"period":"2023-12-31","value":361998585.6658369},{"period":"2022-12-31","value":350271885.53621036}],"grossProfit":423085930.831069,"grossProfitHistory":[{"period":"2025-12-31","value":423085930.831069},{"period":"2024-12-31","value":346852792.5199109},{"period":"2023-12-31","value":302385201.6443339},{"period":"2022-12-31","value":310671274.2737243}],"rdSpend":75292638.67903392,"rdSpendHistory":[{"period":"2025-12-31","value":75292638.67903392},{"period":"2024-12-31","value":73971151.1789169},{"period":"2023-12-31","value":94344768.3641927},{"period":"2022-12-31","value":103153136.05021924}],"sgaSpend":153308320.65145513,"operatingIncome":85892451.75111412,"operatingIncomeHistory":[{"period":"2025-12-31","value":85892451.75111412},{"period":"2024-12-31","value":73486989.6401837},{"period":"2023-12-31","value":48950985.81726195},{"period":"2022-12-31","value":30713252.78700516}],"netIncome":44999952.22058804,"netIncomeHistory":[{"period":"2025-12-31","value":44999952.22058804},{"period":"2024-12-31","value":59331381.24171637},{"period":"2023-12-31","value":51293641.80273578},{"period":"2022-12-31","value":21432304.02144899}],"eps":0.73,"epsHistory":[{"period":"2025-12-31","value":0.73},{"period":"2024-12-31","value":0.96},{"period":"2023-12-31","value":0.83},{"period":"2022-12-31","value":0.35}],"cash":63371404.97394576,"cashHistory":[{"period":"2025-12-31","value":63371404.97394576},{"period":"2024-12-31","value":69517454.06623916},{"period":"2023-12-31","value":110830636.29354866},{"period":"2022-12-31","value":107778056.99384002}],"totalAssets":1557183695.2882125,"totalLiabilities":574488701.9437132,"totalDebt":354073960.9645246,"equity":972005971.4724267,"operatingCashflow":134303245.58674496,"operatingCashflowHistory":[{"period":"2025-12-31","value":134303245.58674496},{"period":"2024-12-31","value":134290168.1060555},{"period":"2023-12-31","value":134740537.50747016},{"period":"2022-12-31","value":45207830.16301727}],"capex":-90887357.94912499,"capexHistory":[{"period":"2025-12-31","value":-90887357.94912499},{"period":"2024-12-31","value":-121972392.19405158},{"period":"2023-12-31","value":-161532415.7786675},{"period":"2022-12-31","value":-148935092.22840667}],"freeCashflow":43415887.637619965,"dividendsPaid":-22218711.92319411,"buybacks":null,"employees":1785,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":62320274.49839242,"ebit":44280270.810945176,"ebitda":44280270.810945176,"period":"2026-03-31","revenue":153252776.9398003,"epsBasic":0.56,"netIncome":34769844.10193102,"rdExpense":14360813.977797475,"epsDiluted":0.56,"grossProfit":121197441.70394409,"operatingIncome":43582383.15335352},{"sga":-38482296.5123146,"ebit":6103488.202438619,"ebitda":6103488.202438619,"period":"2025-12-31","revenue":131463927.59474237,"epsBasic":null,"netIncome":-1710099.2767424686,"rdExpense":20323702.544941798,"epsDiluted":null,"grossProfit":101347226.18248157,"operatingIncome":10248214.45693518},{"sga":10552557.309413346,"ebit":12071769.231262593,"ebitda":12071769.231262593,"period":"2025-06-30","revenue":119947867.25495957,"epsBasic":null,"netIncome":5866979.451435872,"rdExpense":20834549.4425678,"epsDiluted":null,"grossProfit":97247024.52075273,"operatingIncome":12440652.363302803},{"sga":60875662.078998126,"ebit":21341096.652438357,"ebitda":21341096.652438357,"period":"2025-03-31","revenue":135230807.30134684,"epsBasic":0.24,"netIncome":14751320.722899802,"rdExpense":16697371.478065379,"epsDiluted":0.24,"grossProfit":109910353.97827065,"operatingIncome":32876159.314388953},{"sga":-55718136.492540345,"ebit":-3496113.6224643555,"ebitda":-3496113.6224643555,"period":"2024-12-31","revenue":80663089.54276213,"epsBasic":null,"netIncome":-2012728.829408742,"rdExpense":17371011.727684326,"epsDiluted":null,"grossProfit":57252902.12399243,"operatingIncome":10766256.597420562}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":50.1,"previousClose":51.23,"fiftyTwoWeekHigh":79.8,"fiftyTwoWeekLow":40.1,"fiftyTwoWeekRange":"40.1 - 79.8","fiftyDayAverage":45.99,"twoHundredDayAverage":53.51,"beta":0.56,"enterpriseValue":3488938749.8289356,"forwardPE":29.8,"priceToBook":3.1,"priceToSales":5.65,"enterpriseToRevenue":6.34,"enterpriseToEbitda":19.63,"pegRatio":0,"ebitda":177751299.97214976,"ebitdaMargin":32.3,"freeCashflow":-45813385.03555968,"operatingCashflow":129302879.80792256,"totalDebt":377452890.88965374,"debtToEquity":37.3,"currentRatio":0.99,"returnOnAssets":3.9,"returnOnEquity":6.8,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":43.06,"targetHighPrice":43.06,"targetLowPrice":43.06,"dividendRate":0.2,"payoutRatio":0.19,"fiveYearAvgDividendYield":0.36,"exDividendDate":1750118400,"insiderHeldPercent":44.7,"institutionHeldPercent":11.6,"sharesOutstanding":420733843,"floatShares":236721689,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.05,"epsForward":1.68,"revenuePerShare":8.9,"bookValue":16.15,"officers":[{"age":62,"name":"Dr. Lieming  Ding","title":"Founder, Chairman of the Board, CEO & GM"},{"age":48,"name":"Ms. Jia  Tong","title":"CEO & Director"},{"age":54,"name":"Mr. Jianxun  Fan","title":"VP, CFO & Director"},{"age":57,"name":"Mr. Jiang  Wan","title":"Senior VP, President of Global Sales & Director"},{"age":68,"name":"Dr. Mao  Li","title":"President of R&D, Chief Medical Officer & Director"},{"age":42,"name":"Mr. Lingxi  Wu","title":"Head of Chairman Office & Board Secretary"},{"age":null,"name":"Hena  Shi","title":"VP, COO & General Manager of Oncology Business Department"},{"age":34,"name":"Mr. Shi Zhe  Ding","title":"Director & Assistant to the Chairman"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.bettapharma.com","phone":"86 571 8613 0357"}}